Every Form 4 that Catalyst Pharmaceutical Inc. (CPRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPRX filings page.
Catalyst Pharmaceuticals Chief Legal Officer Brian Elsbernd reported the cancellation of his equity interests in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. On July 15, 2026, 242,501 common shares were disposed of at $31.50 per share, and all reported RSUs and stock options were cancelled and converted into cash rights using a $31.50 per share amount in the payout formulas. Following these transactions, the filing lists zero remaining holdings of the reported securities.
CATALYST PHARMACEUTICALS director Daniel J. Curran reported dispositions of equity awards to the issuer in connection with the consummation of a Merger. On 2026-07-15, 5,468 restricted stock units and stock options over 18,115 and 40,000 shares of common stock were cancelled. Each restricted stock unit represented a contingent right to receive one share, and each award was converted into a right to receive a cash payment based on a $31.50 per-share merger price, less the applicable option exercise prices. All reported options and RSUs vested in full at closing, and these derivative positions now show zero shares following the transactions.
Catalyst Pharmaceuticals director David S. Tierney reported the disposition of 383,314 shares of common stock at $31.50 per share to the issuer on July 15, 2026, in connection with the acquisition by Angelini Pharma S.p.A. All reported RSUs and fully vested stock options were cancelled at closing and converted into cash based on the $31.50 merger price, leaving no reported remaining holdings of these securities.
Steve Miller, chief operating and scientific officer of Catalyst Pharmaceuticals, reported the disposition to the issuer of 1,093,803 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).
On the same date, all reported restricted stock units (47,826; 16,534; 11,873 underlying shares) and multiple option grants (including 158,454 options at $22.77, 202,958 at $21.12 and 275,000 at $3.42) were canceled and converted into rights to receive cash based on a $31.50 reference price per share. Each option and RSU vested in full at consummation of the Merger, and reported holdings after these transactions were 0 shares and 0 derivative securities.
Catalyst Pharmaceuticals director Tamar Thompson reported the disposition of all reported equity positions in connection with the acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A. On 2026-07-15, 3,773 shares of common stock were surrendered at $31.50 per share, and multiple restricted stock unit and stock option awards covering specified shares were cancelled and converted into cash based on the $31.50 per-share merger price. Following these transactions, the reported holdings show 0 shares and 0 derivative awards remaining for the positions covered.
CATALYST PHARMACEUTICALS, INC. Chief HR Officer Gregg Russo disposed of equity in connection with the acquisition by Angelini Pharma S.p.A. at $31.50 per share. The report shows the return of 476 common shares plus multiple RSUs and stock options to the issuer for cash consideration. After these transactions, no holdings in the reported securities remain.
Patrick J. McEnany, chairman of Catalyst Pharmaceuticals, reported the disposition of 4,171,559 shares of common stock at $31.50 per share in connection with the acquisition of Catalyst by Angelini Pharma S.p.A., and this Form 4 shows 0 shares of common stock held directly afterward.
The reported restricted stock units and stock options covering additional shares were cancelled at merger closing and converted into rights to receive cash payments based on a $31.50 per-share value, with each award vesting in full at consummation.
CATALYST PHARMACEUTICALS, INC. director Donald A. Denkhaus reported disposing of 498,773 shares of common stock at $31.50 per share on July 15, 2026, in a disposition to the issuer completed in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).
On the same date, all reported restricted stock units and stock options, covering additional shares of common stock, were cancelled and converted into rights to receive cash payments based on the $31.50 per-share merger consideration, and his reported holdings in these securities fell to 0.
Catalyst Pharmaceuticals Chief Commercial Officer Jeffrey Del Carmen reported issuer dispositions on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. He disposed of 14,337 common shares at $31.5000 per share, and all reported restricted stock units and stock options vested in full, were canceled, and converted into rights to receive cash payments calculated using a $31.50 per-share merger price. Following these transactions, he reports no remaining Catalyst equity holdings, including common stock, RSUs, or stock options.
Catalyst Pharmaceuticals Chief Strategy Officer Preethi Sundaram reported dispositions tied to the company’s acquisition by Angelini Pharma S.p.A. On July 15, 2026 she disposed of 54,804 shares of common stock at $31.50 per share, and all reported RSUs and stock options were canceled and converted into cash rights, leaving her with no reported common or derivative holdings.
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported the disposition of 271,266 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A.
All reported restricted stock units and stock options were cancelled and converted into cash rights based on the $31.50 merger price, with option payouts equal to the merger price minus the exercise price per share. After these transactions, no holdings of the reported awards remain.
CATALYST PHARMACEUTICALS, INC. reports that Chief Medical Officer William T. Andrews disposed of 2,309 common shares at $31.50 per share in a transaction with the issuer, in connection with the acquisition by Angelini Pharma S.p.A. (the Merger).
On the same date, all of his reported RSUs (29,776 and 12,209 units) and stock options (98,652 at a $22.77 exercise price and 124,447 at $24.90) vested, were cancelled, and converted into cash rights based on the $31.50 merger price, leaving no reported remaining holdings in these awards.
CATALYST PHARMACEUTICALS director Molly Harper reported the disposition to the issuer of 3,694 common shares at $31.50 per share on July 15, 2026, in connection with the acquisition of the company by Angelini Pharma S.p.A. In the same merger-related event, she also disposed of multiple restricted stock units and stock options, which were cancelled and converted into cash rights calculated using the $31.50 merger price, leaving the reported positions at zero.
Catalyst Pharmaceuticals chief financial officer Michael Wayne Kalb reported dispositions of common stock, restricted stock units and stock options on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. The reported awards vested in full, were cancelled, and converted into rights to receive cash based on a price of $31.50 per share or, for options, the excess of $31.50 over each option’s exercise price, leaving the reported positions at zero.
Catalyst Pharmaceuticals Chief Medical Officer William T. Andrews reported routine equity compensation activity involving restricted stock units that convert into common stock. On June 3, 2026, 3,052 restricted stock units were exercised into 3,052 shares of common stock at a conversion price of $0.0000 per share.
Of these, 743 shares were withheld by Catalyst Pharmaceuticals to cover applicable tax obligations, described as a tax-withholding disposition. After this withholding, Andrews directly holds 2,309 shares of common stock. Footnotes explain that each restricted stock unit represents a right to receive one common share upon vesting and that the related derivative securities vest in five equal annual tranches on June 2 of each year from 2026 through 2030.
Catalyst Pharmaceuticals Chief HR Officer Gregg Russo reported equity compensation activity. On February 17, 2026, 687 restricted stock units vested and converted into an equal number of common shares at $0.00 per share. Of these, 211 shares were withheld to cover taxes, leaving 476 shares delivered. The derivative award vests in five equal annual tranches each February 13 from 2026 through 2030, with shares required to be delivered within sixty days of vesting.
Catalyst Pharmaceuticals President and CEO Richard J. Daly reported equity compensation activity. On January 5, 2026, 42,105 restricted stock units vested and were converted into an equal number of Catalyst common shares at a price of $0 per share. According to the filing, this award vests in five equal annual tranches from January 1, 2025 through January 1, 2029.
To cover withholding taxes tied to the vesting, the company withheld 10,577 common shares, leaving Daly with 271,266 common shares directly owned after the transactions. He also reported 2,618,539 restricted stock units beneficially owned following this vesting event.
Catalyst Pharmaceuticals director Molly Harper reported exercising stock options and selling common shares of the company. On 12/12/2025, she exercised options to purchase 20,000 shares of common stock at an exercise price of $5.78 per share, converting them into common shares. She then sold common stock in several open-market transactions, including 15,527 shares at a weighted average price of $23.198, 4,473 shares at $23.734, and 6,746 shares at $23.06 per share. Following these transactions, she directly beneficially owned 2,360 shares of common stock and 128,497 options to purchase common stock. The sales were made on the open market for personal reasons and to help fund the option exercise, and were not due to any disagreement with the company.
Catalyst Pharmaceuticals, Inc. (CPRX) chairman of the board and director Patrick J. McEnany reported stock gifts to family trusts. On 12/01/2025, he made bona-fide gifts of common stock, par value $0.001 per share, recorded at a price of $0 per share, classified under transaction code "G" for gifts. After the reported transactions, he directly beneficially owned 4,148,477 shares of Catalyst Pharmaceuticals common stock. The explanation notes that the gifts were to irrevocable trusts for family members who do not share his household, and he is not a trustee and has no direct or indirect influence over the trusts' investment decisions.
Catalyst Pharmaceuticals (CPRX) reported equity transactions by its Chief Strategy Officer on a Form 4. On 11/21/2025, the officer acquired 5,603 shares of common stock through the exercise of derivative awards and had 1,364 shares withheld to cover taxes, leaving 45,320 shares of common stock owned directly.
The filing also shows new derivative awards dated 11/20/2025, including options to purchase 106,873 shares of common stock at an exercise price of $22.77 per share and 32,257 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual tranches from November 20, 2026 through November 20, 2028. Additional RSUs that vest in thirds each year from November 21, 2025 to November 21, 2027 are also reported.
Catalyst Pharmaceuticals (CPRX) reported insider equity activity by its Chief Operating and Scientific Officer on a Form 4. On November 20, 2025, the officer received options to purchase 158,454 shares of common stock at an exercise price of $22.77 per share. These options vest in three equal installments on November 20, 2026, November 20, 2027, and November 20, 2028.
Also on November 20, 2025, the officer was granted 47,826 restricted stock units (RSUs), with shares delivered upon vesting. A separate RSU award vests in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027, and shares must be delivered within sixty days of each vesting date; the first tranche of 8,267 shares was delivered on November 21, 2025. Following these transactions, the officer directly owned 1,067,930 shares of common stock.
Catalyst Pharmaceuticals (CPRX) reported an equity compensation grant to its Chief HR Officer on November 20, 2025. The officer received options to purchase 20,531 shares of common stock at an exercise price of $22.77 per share, along with 6,197 restricted stock units (RSUs). The options vest in three equal annual installments, with one-third vesting on November 20, 2026, one-third on November 20, 2027, and one-third on November 20, 2028. Each RSU represents a right to receive one share of common stock upon vesting, and shares will be delivered to the officer when the RSUs vest. Following these awards, the officer beneficially owns 66,276 options and 72,473 RSUs in total.
Catalyst Pharmaceuticals (CPRX) reported insider equity awards for a director on a Form 4. On November 20, 2025, the reporting person received options to purchase 18,115 shares of common stock at an exercise price of $22.77, and 5,468 restricted stock units (RSUs). On November 21, 2025, 947 RSUs were settled in common stock, increasing the director’s directly held common shares to 2,360.
Following these transactions, the director held 116,555 stock options, 121,076 RSUs, and 2,360 shares of common stock, all directly. The options and RSUs generally vest in three equal annual tranches on specified dates in 2025, 2026, 2027, and 2028, with shares required to be delivered within sixty days of vesting.
Catalyst Pharmaceuticals Executive Vice President and CFO Michael W. Kalb reported equity award activity in company stock. On 11/21/2025, he acquired 6,894 shares of common stock through an option exercise (code M) and had 2,485 shares withheld to cover taxes on vesting (code F), leaving him with 8,606 shares of common stock held directly.
He was granted options to purchase 131,536 shares at an exercise price of $22.77 per share, expiring on 11/20/2032. These options vest in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028. He also received 39,701 restricted stock units, which convert into common shares upon vesting, and additional RSU-related vesting of 6,894 shares scheduled in equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.
Catalyst Pharmaceuticals, Inc. (CPRX) director David S. Tierney reported equity awards and a share delivery around late November 2025. On 11/20/2025, he was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, vesting in three equal annual installments on November 20, 2026, 2027, and 2028. He was also granted 5,468 restricted stock units (RSUs), which convert into the same number of common shares upon vesting on the same three-year schedule.
On 11/21/2025, 947 RSUs were settled into common stock, adding 947 shares of common stock to his direct holdings and reducing his derivative balance. After these transactions, he directly owned 380,567 shares of common stock and held 180,910 derivative securities, including options and RSUs, all reported as directly owned.
Catalyst Pharmaceuticals, Inc. (CPRX) reported an insider equity award for its Chairman of the Board and Director, Patrick J. McEnany. On 11/20/2025, he received options to purchase 34,921 shares of common stock at an exercise price of $22.77 per share, along with 10,540 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
On 11/21/2025, 1,775 RSUs were settled, and McEnany acquired 1,775 shares of common stock, increasing his directly held common stock to 4,283,477 shares. Following these transactions, he also beneficially owned 1,881,816 derivative securities, including options and RSUs that will deliver common shares as they vest and are settled.
Catalyst Pharmaceuticals, Inc. (CPRX) reported an insider equity transaction by a director. The filing shows the acquisition of 947 shares of common stock, following the exercise or settlement of equity awards, bringing the director’s directly held common stock position to 7,693 shares.
The director was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. In addition, the director received 5,468 restricted stock units (RSUs), each representing a right to one share of common stock upon vesting. These options and RSUs generally vest in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028, with a separate RSU grant vesting in equal parts on November 21, 2025, November 21, 2026, and November 21, 2027.
Catalyst Pharmaceuticals (CPRX) President and CEO Richard J. Daly, who also serves as a director, reported new equity awards and related share activity. On November 21, 2025, he acquired 20,006 shares of common stock through the vesting of restricted stock units and had 7,872 shares withheld to cover taxes, leaving him with 238,928 shares of common stock held directly.
On November 20, 2025, he received options to purchase 381,948 shares of common stock at an exercise price of $22.77 per share, vesting in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028. He was also granted 115,283 restricted stock units that vest on the same schedule. Following these transactions, Daly beneficially owns 2,661,978 derivative securities tied to Catalyst common stock.
Catalyst Pharmaceuticals (CPRX) director reports equity awards and vesting activity. A board member filed a Form 4 disclosing equity-based compensation and related share delivery in November 2025.
The reporting person was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 on November 20, 2025. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028. The filing also shows an award of 5,468 restricted stock units (RSUs) on November 20, 2025, each convertible into one share upon vesting.
On November 21, 2025, 947 RSUs were converted, and the corresponding 947 common shares were delivered to the director. Following these transactions, the director reports beneficial ownership of 496,026 shares of Catalyst Pharmaceuticals common stock directly, along with derivative holdings consisting of options and RSUs that will deliver additional shares as they vest over time.
Catalyst Pharmaceuticals (CPRX) reported insider equity awards for its Chief Compliance/Legal Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
The officer was also granted 29,776 restricted stock units (RSUs), which convert into common shares upon vesting, with the same three-year vesting schedule. On November 21, 2025, 5,161 shares underlying RSUs were delivered, while 2,030 shares were withheld to cover taxes. After these transactions, the officer directly held 234,170 shares of common stock and 969,876 derivative securities, mainly options and RSUs.
Catalyst Pharmaceuticals, Inc. (CPRX) reported insider equity activity for its Chief Commercial Officer on a Form 4. On 11/21/2025, the officer exercised 5,603 shares of common stock and had 1,641 shares withheld to cover taxes, leaving 3,962 common shares beneficially owned directly. The filing also shows a grant on 11/20/2025 of options to purchase 106,873 shares of common stock at an exercise price of $22.77, vesting in three equal annual installments on November 20, 2026, 2027 and 2028. In addition, the officer received 32,257 restricted stock units tied to common stock, and RSUs covering 5,603 shares were settled into stock on 11/21/2025. Following these transactions, the officer holds 1,064,535 derivative securities, including options and RSUs, all reported as directly owned.
Catalyst Pharmaceuticals, Inc. (CPRX) director Daniel J. Curran reported new equity awards dated 11/20/2025. He received options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, which vest in three equal annual installments on November 20, 2026, 2027 and 2028. Following this grant, he beneficially owns 58,115 stock options. He was also awarded 5,468 restricted stock units (RSUs), each representing a right to receive one share of common stock upon vesting, increasing his RSU holdings to 63,583 units. All holdings are reported as directly owned.
Catalyst Pharmaceuticals (CPRX) reported an equity award for its Chief Medical Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. The grant also included 29,776 restricted stock units (RSUs), each representing one share of common stock upon vesting.
The derivative securities vest in three equal parts: one‑third on November 20, 2026, one‑third on November 20, 2027, and one‑third on November 20, 2028. After these awards, the officer beneficially owns 238,360 options and 268,136 RSUs in total, aligning compensation with the company’s long-term stock performance.